Development of pharmacokinetic simulator for adrenaline infusio

Not Applicable

• Conditions: eft ventricular dysfunction, Aortic/Mitral valve stenosis, Aortic/Mitral valve regurgitation; cardiac disease, circulatory depression; D018487, D001024, D008944

• Registration Number: JPRN-jRCT1031230653
• Lead Sponsor: Sasaki Makoto

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-02-27
• Last Update Posted: 27 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

(1) Moderate or severe aortic/mitral valve regurgitation
(2) Moderate or severe aortic/mitral valve stenosis
(3) Left ventricular ejection fraction <=50%

Exclusion Criteria

Disease, condition, and physical status that affect adrenaline metabolism.
(1) Off pump CABG
(2) Arrhythmia requiring care
(3) Patients who are administered with catecholamine
(4) Patients under mechanical ventilation
(5) Unruptured cerebral aneurysm of surgical indication
(6) Allergy or contradiction for investigative drugs
(7) Dialysis patients
(8) Hepatic dysfunction (Child-Pugh grade C)
(9) One lung ventilation
(10) Height<150 cm
(11) BMI>=30 kg/m2
(12) Patients administered with anti-psychotic or -depressant drug
(13) Patients administered with monoamine oxidase inhibitor
(14) Patients administered with steroids
(15) Hyperthyroidism
(16) Patients considered inappropriate for trial

Study & Design

• Study Type: Interventional
• Study Design: Not specified